Research

*October 2022* Targeted treatment options for patients with HER2-mutant non–small cell lung cancer (NSCLC) have been slow to reach benchmarks for approval given the limited patient populations harboring this disease characteristic. Three classes of agents have demonstrated efficacy in patients with HER2-mutant disease: tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and…

*October 2022* Drs Benjamin Levy, Neil Morganstein, and Bhuvana Ramkumar discuss challenges of procuring for molecular testing in patients with NSCLC. Watch video here.

*October 2022* Dr. Neil Love and Dr. Pasi Janne discuss the current and future management of EGFR+ NSCLC.  Listen to the audio or read the transcription.

*September 2022* The clinical significance of gene fusions detected by DNA-based next generation sequencing remains unclear as resistance mechanisms to EGFR tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer. By studying EGFR inhibitor-resistant patients treated with a combination of an EGFR inhibitor and a drug targeting the putative…

*October 2022* What happens when your cancer becomes resistant to your course of treatment and progresses? Dr. David Gandara, professor emeritus and co-director of UC Davis Comprehensive Cancer Center’s Center for Experimental Therapeutics, discussed a number of options. The good news is that it turns out there’s a lot that…

*September 2022*  From Dr. Julien Mazieres' presentation at ESMO 2022

*September 2022* Topline data presented at ESMO 2022 showed DZD9008 met its primary end point of objective response rate and had a benign safety profile in non–small cell lung cancer with EGFR exon 20 insertion mutations. DZD9008 (sunvozertinib) in patients with platinum-pretreated non–small cell lung cancer (NSCLC) with EGFR exon…

*September 2022* Trastuzumab deruxtecan (Enhertu) demonstrated clinically meaningful benefit and a favorable safety profile at the lower of 2 dose levels in patients with HER2-mutated non–small cell lung cancer (NSCLC), according to interim results of the DESTINY-Lung02 trial (NCT04644237) presented at the 2022 European Society for Medical Oncology (ESMO) Congress.1…

*September 2022* Fine particulate matter from the combustion of fossil fuels seemed to trigger non-small cell lung cancer (NSCLC) in never smokers through a process of "tumor promotion," according to a study on the etiology of EGFR-mutated disease. The link was first suggested decades ago and long overlooked, but now…

*June 2022* Highlights: Alternation of osimertinib and afatinib was evaluated for patients with metastatic treatment-naïve EGFR-mutated NSCLC in this phase 2 trial. Although the 12-month PFS probability was 70.2%, which did not meet the primary end point, the median PFS was 21.3 months suggesting the promising efficacy of this alternative…